OTCMKTS:EPRSQ EPIRUS Biopharmaceuticals (EPRSQ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About EPIRUS Biopharmaceuticals Stock (OTCMKTS:EPRSQ) 30 days 90 days 365 days Advanced Chart Get EPRSQ alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.Read More… Receive EPRSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EPIRUS Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EPRSQ Stock News HeadlinesChengdu Easton Biopharmaceuticals Co. Ltd. AMay 27, 2024 | wsj.comEiger Biopharmaceuticals Inc (EIGR)February 23, 2024 | investing.comThe Hidden Energy Source Backed by Billionaires Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah Mountains in Utah. Bezos, Buffett, and Gates are getting involved. But few Americans know why this remote patch of land is suddenly worth billions. One of our own insiders even filed a FOIA request in Washington to get to get the truth.May 24, 2025 | Stansberry Research (Ad)EPIRUS Biopharmaceuticals Inc EPRSQFebruary 17, 2024 | morningstar.comSk Biopharmaceuticals Co Ltd (326030)May 11, 2023 | investing.comBiopharmaceuticals Contract Manufacturing Market Report 2023-2033May 9, 2023 | finance.yahoo.comEpirus, Greece - Weather Forecasts | Maps | News - Yahoo WeatherApril 30, 2023 | yahoo.comChengdu Olymvax Biopharmaceuticals Inc. AMarch 29, 2023 | wsj.comSee More Headlines EPRSQ Stock Analysis - Frequently Asked Questions How were EPIRUS Biopharmaceuticals' earnings last quarter? EPIRUS Biopharmaceuticals, Inc. (OTCMKTS:EPRSQ) released its quarterly earnings data on Wednesday, August, 20th. The biopharmaceutical company reported ($1.52) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by $0.32. How do I buy shares of EPIRUS Biopharmaceuticals? Shares of EPRSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/20/2014Today5/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EPRSQ Previous SymbolNASDAQ:EPRS CIK1135906 Webwww.epirusbiopharma.com Phone(617) 600-3497Fax617-301-7010Employees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (OTCMKTS:EPRSQ) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredThe Hidden Energy Source Backed by Billionaires Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EPIRUS Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EPIRUS Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.